TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02967705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain management group
Description: Chronic pain patients participate in a peer group. They are provided information about chronic pain self-management based on biopsychosocial framework.
Study: NCT02221349

Intervention type: DEVICE
Group type: OTHER
Intervention: Potassium oxalate
Description: Professionally applied (liquid) and self applied (gel)

Intervention type: DEVICE
Group type: OTHER
Intervention: Potassium oxalate
Description: Professionally applied (liquid) and self applied (gel)

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium fluoride paste
Description: Toothpaste used by subject

Intervention type: DRUG
Group type: OTHER
Intervention: Stannous fluoride paste
Description: Toothpaste used by subject
Study: NCT03906383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Description: Brief reversible restriction of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
Study: NCT02582606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular meal pattern
Description: a 14-day period of eating 6 meal per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Irregular meal pattern
Description: a 14-day period of eating between 3 and 9 meal per day
Study: NCT02529982

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01931787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV
Study: NCT02595671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Super Coach
Description: Receive Digital Super Coach during 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Super Coach
Description: Receive Digital Super Coach during 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional face to face PA & dietitian
Description: Receive 7 face-to-face contacts (dietary and physical activity advice)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Super Coach + minimal coaching
Description: Receive 3 face-to-face contacts (dietary and physical activity advice)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting Group
Description: Receive Digital Super Coach during 12 weeks, after 12 weeks of no treatment
Study: NCT02742753

Intervention type: OTHER
Intervention: Data collection
Description: Data will be collected retrospectively linking regional patient-level data prospectively captured in real-world clinical setting with mandatory national healthcare registries from 2004 to 2013.
Study: NCT03880032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Intervention for Anxiety
Description: Happy Mother Healthy Baby (HMHB) is a CBT-based psychosocial intervention for expectant women experiencing anxiety during their pregnancy. Strategies such as empathetic listening, thought challenging, behavior activation, problem management, take-home exercises, and family involvement are employed by HMHB.
Study: NCT03462420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy program
Description: The physical therapy program will be chosen by the treating therapist. However, the most common physiotherapy interventions include therapeutic exercises, joint mobilization techniques and electrotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy program
Description: The physical therapy program will be chosen by the treating therapist. However, the most common physiotherapy interventions include therapeutic exercises, joint mobilization techniques and electrotherapy.
Study: NCT04967781

Intervention type: BEHAVIORAL
Intervention: autoimmunity
Description: autoimmunity is characterized as self attacking from self immune system, which may involve in the severe progression of COVID-19.
Study: NCT03961217

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy as part of cancer treatment

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy as part of cancer treatment

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy as part of cancer treatment
Study: NCT03947450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Skin Fibroblasts
Description: The site or whole stump will be injected with autologous fibroblasts

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The site or whole stump will be injected medium only without autologous skin fibroblasts
Study: NCT02715336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovulation induction with hCG and Lupron (GnRH agonist)
Description: Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovulation induction with hCG and Lupron (GnRH agonist)
Description: Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovulation induction with hCG and Lupron (GnRH agonist)
Description: Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.
Study: NCT00938717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide or Matching Placebo
Description: Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linaclotide or Matching Placebo
Description: Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
Study: NCT01898897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural catheter insertion
Description: A catheter is placed in the epidural space at thoracic level. Analgesia is realised with local anesthetics (Bupivacaine plain 0.125%), administered from the beginning of surgical intervention and 12 hours postoperative on the postoperative care unit and intensive care unit at a rate of 6-8 ml/hour.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot assisted laparoscopic urogenital surgery
Description: The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robot assisted laparoscopic urogenital surgery
Description: The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.
Study: NCT03093753

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 1)
Description: Control meal will comprise of 50 g glucose dissolved in 200 ml water, to which the response of the test meals will be compared to

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test (study 1)
Description: The test meal will comprise 50 g glucose in 200 ml water plus 50 mg oleuropein from olives

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 2)
Description: Control meal will comprise 109 g white bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test (study 2)
Description: The test meal will comprise 109 g white bread plus 50 mg oleuropein from olives dissolved in 200 ml water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 3)
Description: Control meal will comprise whole-meal bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test (study 3)
Description: The test meal will comprise whole-meal bread plus 50 mg oleuropein from olives dissolved in 200 ml water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 4)
Description: Control meal will comprise 50 g sucrose in 200 ml water, to which the response of the test meals will be compared to

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test (study 4)
Description: The test meal will comprise 50 g sucrose in 200 ml water plus 50 mg oleuropein from olives

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 5)
Description: Control meal will comprise 25 g sucrose in 200 ml water, to which the response of the test meals will be compared to

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test (study 5)
Description: The test meal will comprise 25 g sucrose in 200 ml water plus 160 mg oleuropein from olives

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 6)
Description: Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test (study 6)
Description: High carbohydrate diet (23% fat, 55% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (study 7)
Description: Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test (study 7)
Description: High fat diet (44% fat, 34% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
Study: NCT01535495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol XL 120mg by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol XL 120mg by mouth once daily
Study: NCT00078325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg/day
Description: Armodafinil 250 mg once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg/day
Description: Armodafinil 150 mg once daily in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets once daily in the morning
Study: NCT03054922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: IV infusion of 0.9% NaCl throughout surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer
Description: IV infusion of lactated ringer throughout surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normosol-R Inj
Description: IV infusion of Normosol throughout surgery.
Study: NCT00786565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced Akreos Adapt in one operated eye.
Description: Cataract surgery to implant the assigned IOL according to randomized schedule.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Akreos Adapt in fellow operated eye.
Description: Cataract surgery to implant the assigned IOL according to randomized schedule.
Study: NCT00959998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered Acupressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered Acupressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-administered Acupressure
Study: NCT01699542

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WallFlex Esophageal RX Fully Covered Stent
Description: Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal Bougie Dilator Per Investigator preference
Description: Commercially available Esophageal Bougie Dilator Per Investigator preference
Study: NCT03632590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Citrate
Description: 450 mg of Magnesium Citrate per day (6 capsules per day) for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 450 mg of Magnesium Sulfate per day (6 capsules per day) for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Oxide
Description: 450 mg of Magnesium Oxide per day (6 capsules per day) for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will contain starch (Amylum solani) for 24 weeks
Study: NCT05513625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritelivir
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESO and pritelivir
Description: oral administration
Study: NCT02047253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered prior to administration of Study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Administered orally twice daily
Study: NCT02693522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eutropin
Description: Subcutaneous injection
Study: NCT03805750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD/THC
Description: Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matched Placebo
Study: NCT01037660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1 gram per day
Study: NCT01034592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 2.5 mg/wk up to 5 mg 3x/wk
Study: NCT01987960

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 1 to 3 mg/day, once daily dose, tablets, orally
Study: NCT00317720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.~If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
Study: NCT02241382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal Electrocardioversion
Description: Cardioversion by internal shock application via the implanted ICD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Electrocardioversion
Description: Cardioversion by external shock application via a cardioverter/defibrillator.
Study: NCT03745833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mindfulness
Description: Participating patients will be provided with a VR headset (pre-programmed with mindfulness content) after lunch for 15 minutes with supervision while on strict bedrest. The headset will be collected following the intervention. Patients are currently provided with a post-meal survey following all meals as part of the standard of care, and will complete the survey following the lunchtime intervention.
Study: NCT00946504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)
Study: NCT03583983

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized Health Recommendations
Description: Includes 3-month gym membership, personalized exercise and meal plans, and genetic information related to health and wellness traits. The genetic information provided to study participants will consist of scores ranging from 0 to 100 based on the population percentile of the combined effects of many genetic variants, herein referred to as polygenic scores (PGS). PGS for approximately twenty traits related to health, fitness and nutrition will be provided to study participants. These traits are chosen for their relevance to healthy lifestyle habits (e.g. genetic predisposition to adiposity or muscle strength), entertainment value (e.g. preference for mornings) or both (e.g. bitterness taste perception, which while entertaining can also help guide vegetable choices).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Generic Health Recommendations
Description: Includes 3-month gym membership and generic recommendations (Canada Food Guide / Health Canada Physical Activity guidelines)
Study: NCT01045798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin acetate
Description: 70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
Study: NCT04446962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
Study: NCT02372565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook and text Message
Description: Culturally-relevant physical activity promotion program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Print-based Intervention
Description: Non-culturally relevant physical activity promotion program
Study: NCT02536313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT04357873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab; vorinostat
Description: Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression
Study: NCT03761875

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample CHB patients
Description: During a boold sample at only one follow up visit:~* 3 tubes EDTA 10 ml per patient~* 1 tube Paxgene 1ml~* 1 dry tube per patient

Intervention type: OTHER
Group type: OTHER
Intervention: boold sample Control group
Description: * 2 tubes EDTA ideally age and sex matched to CHB patient.~* 1 tube Paxgene 1ml~* 1 dry tube
Study: NCT02720770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norditropine simplex
Study: NCT03130062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The following muscular clusters were exerted: latissimus dorsi, deltoid, pectoralis major , triceps brachialis, biceps brachialis, quadriceps, hamstring, thigh adductor muscles, thigh abductor muscles and gastrocnemius.
Study: NCT04291248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105
Description: AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105
Description: AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor.
Study: NCT00086970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Description: Given IV
Study: NCT04402970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa Inhalation Solution
Description: Nebulized dornase alfa